Connor Clark & Lunn Investment Management Ltd. Has $11.72 Million Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 665.1% in the third quarter, Holdings Channel reports. The institutional investor owned 74,625 shares of the company’s stock after acquiring an additional 64,872 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in TransMedics Group were worth $11,716,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of TMDX. Amalgamated Bank increased its holdings in TransMedics Group by 6.7% during the second quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock worth $168,000 after buying an additional 70 shares during the last quarter. Pitcairn Co. boosted its stake in shares of TransMedics Group by 1.5% in the 1st quarter. Pitcairn Co. now owns 5,378 shares of the company’s stock valued at $398,000 after purchasing an additional 78 shares in the last quarter. Harbour Capital Advisors LLC increased its stake in TransMedics Group by 1.7% in the 3rd quarter. Harbour Capital Advisors LLC now owns 4,841 shares of the company’s stock worth $760,000 after purchasing an additional 81 shares during the period. Signaturefd LLC lifted its stake in TransMedics Group by 26.6% in the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after acquiring an additional 93 shares during the period. Finally, Arizona State Retirement System boosted its position in shares of TransMedics Group by 2.1% during the second quarter. Arizona State Retirement System now owns 9,158 shares of the company’s stock valued at $1,379,000 after purchasing an additional 186 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

Insiders Place Their Bets

In other news, insider Tamer I. Khayal sold 2,958 shares of the firm’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $148.24, for a total value of $438,493.92. Following the completion of the transaction, the insider now owns 20,843 shares in the company, valued at $3,089,766.32. This trade represents a 12.43 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Nicholas Corcoran sold 10,000 shares of the stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $176.02, for a total value of $1,760,200.00. Following the transaction, the insider now directly owns 21,105 shares in the company, valued at approximately $3,714,902.10. This represents a 32.15 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 36,958 shares of company stock valued at $5,230,528. 7.00% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research firms have recently weighed in on TMDX. Canaccord Genuity Group decreased their price target on TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a research note on Wednesday. Robert W. Baird reduced their price target on shares of TransMedics Group from $200.00 to $150.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 29th. Needham & Company LLC decreased their price objective on TransMedics Group from $208.00 to $109.00 and set a “buy” rating for the company in a report on Tuesday, October 29th. TD Cowen cut their price objective on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research report on Monday. Finally, Piper Sandler cut their target price on TransMedics Group from $180.00 to $110.00 and set an “overweight” rating on the stock in a research report on Wednesday. One investment analyst has rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, TransMedics Group has an average rating of “Buy” and a consensus price target of $131.80.

TransMedics Group Stock Up 2.8 %

Shares of NASDAQ TMDX opened at $79.34 on Friday. The company has a 50 day simple moving average of $122.08 and a 200-day simple moving average of $138.50. TransMedics Group, Inc. has a 1 year low of $67.77 and a 1 year high of $177.37. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The company has a market capitalization of $2.66 billion, a P/E ratio of 82.13 and a beta of 2.08.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The business had revenue of $108.76 million during the quarter, compared to analyst estimates of $115.00 million. During the same quarter last year, the firm posted ($0.12) EPS. The company’s revenue for the quarter was up 63.7% on a year-over-year basis. On average, equities research analysts predict that TransMedics Group, Inc. will post 1 earnings per share for the current year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.